Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01051999 · ClinicalTrials.gov registry record · Phase 2
Glutamine Supplementation in Cystic Fibrosis
A Phase 2 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01051999 is a Phase 2 study that has completed, run by Emory University. The registered enrollment target is 17 participants.
The verdict
NCT01051999, a Phase 2 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
Patients with cystic fibrosis develop frequent and potentially life-threatening lung infections. Recent studies suggest that the nutrient "glutamine" may help the body fight off infection. Glutamine is an amino acid; a type of nutrient the body requires to build muscle. It is one of the building blocks of protein. During an illness, blood levels of glutamine tend to be lower than normal. Also, many patients with cystic fibrosis have difficulty getting normal levels of nutrients from food. The aim of this study is to see if patients with cystic fibrosis have low levels of glutamine when they experience an infection, and whether a dietary glutamine supplement taken daily for three months can raise these levels. We also want to see if this supplement can improve other blood markers of immunity (the body's ability to defend itself from infection). We hope to enroll 40 people with cystic fibrosis who experience a lung infection, over a one year period, into this study.
Interventions
- DIETARY_SUPPLEMENT Glutamine
- DIETARY_SUPPLEMENT L-alanine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2010-02 |
| Est. Completion | 2011-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01051999
The ClinicalTrials.gov registry entry for NCT01051999 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Glutamine is the first listed.
NCT01051999 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01051999 about?
NCT01051999 is a clinical study titled "Glutamine Supplementation in Cystic Fibrosis". Patients with cystic fibrosis develop frequent and potentially life-threatening lung infections. Recent studies suggest that the nutrient "glutamine" may help the body fight off infection. Glutamine is an amino acid; a type of nutrient the body requires to build muscle. It is one of the building blo...
What is the current status of trial NCT01051999?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2010-02. Estimated completion is 2011-02.
What interventions are being tested in trial NCT01051999?
The interventions under investigation include: Glutamine (DIETARY_SUPPLEMENT), L-alanine (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01051999?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.